Disease system analysis: Basic disease progression models in degenerative disease

Pharmaceutical Research

Volumn 22, Issue 7, 2005, Pages 1038-1049

  Post, Teun M ^a   Freijer, Jan I ^a   DeJongh, Joost ^a,b   Danhof, Meindert ^a,b  

^a Leiden Advanced Pharmacokinetics and Pharmacodynamics (LAP and P) Consultants   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; Clinical endpoints; Disease progression analysis; Disease system analysis; Indirect response model

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY; SYSTEM ANALYSIS;

BIOLOGICAL MARKERS; CHRONIC DISEASE; COMPUTER SIMULATION; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PROTECTIVE AGENTS;

EID: 23744516690     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-005-5641-5     Document Type: Article

References (52)

1. L. B. Sheiner. 1997 Learning versus confirming in clinical drug development Clin. Pharmacol. Ther. 61 275 291
2. A. Sharma W. J. Jusko. 1996 Characterization of four basic models of indirect pharmacodynamic responses J. Pharmacokinet. Biopharm. 24 611 635
3. K. P. Zuideveld H. J. Maas N. Treijtel J. Hulshof P. H. van der Graaf L. A. Peletier M. Danhof. 2001 A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia Am. J. Physiol., Regul. Integr. Comp. Physiol. 281 R2059 R2071
4. N. L. Dayneka V. Garg W. J. Jusko. 1993 Comparison of four basic models of indirect pharmacodynamic responses J. Pharmacokinet. Biopharm. 21 457 478
5. W. J. Jusko H. C. Ko. 1994 Physiologic indirect response models characterize diverse types of pharmacodynamic effects Clin. Pharmacol. Ther. 56 406 419
6. P. H. Van der Graaf M. Danhof. 1997 Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling Int. J. Clin. Pharmacol. Ther. 35 442 446
7. P. H. Van Der Graaf E. A. Van Schaick R. A. Math-ot A. P. Ijzerman M. Danhof. 1997 Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors J.Pharmacol. Exp. Ther. 283 809 816
8. P. H. Van der Graaf E. A. Van Schaick S. A. Visser H. J. De De Greef A. P. Ijzerman M. Danhof. 1999 Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo J. Pharmacol. Exp. Ther. 290 702 709
9. S. A. Visser D. R. Huntjens P. H. van der Graaf L. A. Peletier M. Danhof. 2003 Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats J. Pharmacol. Exp. Ther. 307 765 775
10. S. A. Visser C. J. Smulders B. P. Reijers P. H. Van der Graaf L. A. Peletier M. Danhof. 2002 Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats J. Pharmacol. Exp. Ther. 302 1158 1167
11. K. P. Zuideveld J. Rusic-Pavletic H. J. Maas L. A. Peletier P. H. Van der Graaf M. Danhof. 2002 Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats J. Pharmacol. Exp. Ther. 303 1130 1137
12. K. P. Zuideveld N. Treijtel H. J. Maas J. M. Gubbens-Stibbe L. A. Peletier P. H. van Der Graaf M. Danhof. 2002 A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di- n-propylamino)tetralin-induced hypothermia J. Pharmacol. Exp. Ther. 300 330 338
13. P. L. Chan N. H. Holford. 2001 Drug treatment effects on disease progression Annu. Rev. Pharmacol. Toxicol. 41 625 659
14. N. H. Holford K. Peace. 1994 The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials Eur. J. Clin. Pharmacol. 47 17 23
15. N. H. Holford K. Peace. 1992 Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine Proc. Natl. Acad. Sci. USA 89 11466 11470
16. N. H. Holford K. E. Peace. 1992 Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine Proc. Natl. Acad. Sci. USA 89 11471 11475
17. N. H. G. Holford. Understanding disease progression using clinical pharmacology. In M. Danhof, M. Karlsson, and R. J. Powell (eds.), Measurement and Kinetics of in vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, Leiden. Advances in Simultaneous Pharmacokinetic/Pharmacodynamic Modelling, 4th International Symposium, 24-27 April, Noordwijkerhout, 2002.
18. A. J. Stoessl C. S. Lee R. de la Fuente-Fernandez 2003 New concepts and tools in imaging for the study of neurodegenerative disease J. Neural. Transm., Suppl. 65 157 166
19. L. J. Lesko A. J. Atkinson Jr. Jr 2001 Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies Annu. Rev. Pharmacol. Toxicol. 41 347 366
20. W. A. Colburn. 2003 Biomarkers in drug discovery and development: from target identification through drug marketing J. Clin. Pharmacol. 43 329 341
21. W. A. Colburn J. W. Lee. 2003 Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling Clin. Pharmacokinet. 42 997 1022
22. A. J. Atkinson W. A. Colburn V. DeGruttola D. L. DeMets G. J. Downing D. F. Hoth J. A. Oates C. C. Peck R. T. Schooley B. A. Spilker J. Woodcock S. L. Zeger. 2001 Biomarkers and surrogate endpoints in clinical trials: preferred definitions and conceptual framework Clin. Pharmacol. Ther. 69 89 95
23. S. E. Ilyin S. M. Belkowski C. R. Plata-Salaman. 2004 Biomarker discovery and validation: technologies and integrative approaches Trends Biotechnol. 22 411 416
24. L. J. Lesko M. Rowland C. C. Peck T. F. Blaschke. 2000 Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans Pharm. Res. 17 1335 1344
25. O. Sander G. Herborn E. Bock R. Rau. 1999 Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate Ann. Rheum. Dis. 58 281 287
26. S. E. Nissen E. M. Tuzcu P. Schoenhagen B. G. Brown P. Ganz R. A. Vogel T. Crowe G. Howard C. J. Cooper B. Brodie C. L. Grines A. N. DeMaria. 2004 Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 1071 1080
27. M. Crnkic B. Mansson L. Larsson P. Geborek D. Heinegard T. Saxne. 2003 Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept Arthritis Res. Ther. 5 R181 R185
28. F. C. Breedveld P. Emery E. Keystone K. Patel D. E. Furst J.R. Kalden E. W. St Clair M. Weisman J. Smolen P. E. Lipsky R. N. Maini. 2004 Infliximab in active early rheumatoid arthritis Ann. Rheum. Dis. 63 149 155
29. N. H. Holford, P. L. Chan, and J. Nutt. Disease progression in Parkinson's disease-evidence for protective effects of drug treatment. 13th Population Approach Group Conference, Uppsala, Sweden, http://www.page-meeting. org, 2004.
30. C. J. Haagsma P. L. van Riel A. J. de Jong L. B. van de Putte 1997 Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial Br. J. Rheumatol. 36 1082 1088
31. E. N. Jonsson L. B. Sheiner. 2002 More efficient clinical trials through use of scientific model-based statistical tests Clin. Pharmacol. Ther. 72 603 614
32. L. B. Sheiner. 2002 Is intent-to-treat analysis always (ever) enough? Br. J. Clin. Pharmacol. 54 203 211
33. L. B. Sheiner D. B. Rubin. 1995 Intention-to-treat analysis and the goals of clinical trials Clin. Pharmacol. Ther. 57 6 15
34. K. P. Zuideveld A. van Gestel L. A. Peletier P. H. Van der Graaf M. Danhof. 2002 Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan Eur. J. Pharmacol. 445 43 54
35. N. Frey C. Laveille M. Paraire M. Francillard N. H. Holford R. Jochemsen. 2003 Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation Br. J. Clin. Pharmacol. 55 147 157
36. P. Jenner. 2003 Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease Curr. Opin. Neurol. 16 S3 S7
37. P. Jenner. 2002 Pharmacology of dopamine agonists in the treatment of Parkinson's disease Neurology 58 S1 S8
38. C. E. Clarke M. Guttman. 2002 Dopamine agonist monotherapy in Parkinson's disease Lancet 360 1767 1769
39. A. H. Schapira. 2004 Disease modification in Parkinson's disease Lancet Neurol. 3 362 368
40. T. H. Johnston J. M. Brotchie. 2004 Drugs in development for Parkinson's disease Curr. Opin. Investig. Drugs 5 720 726
41. W. C. Koller M. G. Cersosimo. 2004 Neuroprotection in Parkinson's disease: an elusive goal Curr. Neurol. Neurosci. Rep. 4 277 283
42. C. W. Olanow. 2004 The scientific basis for the current treatment of Parkinson's disease Annu. Rev. Med. 55 41 60
43. D. B. Campbell R. Lavielle C. Nathan. 1991 The mode of action and clinical pharmacology of gliclazide: a review Diabetes Res. Clin. Pract. 14 S21 S36
44. G. Pillai R. Gieschke T. Goggin P. Jacqmin R. C. Schimmer J. L. Steimer. 2004 A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis Br. J. Clin. Pharmacol. 58 618 631
45. E. Abadie D. Ethgen B. Avouac G. Bouvenot J. Branco O. Bruyere G. Calvo J. P. Devogelaer R. L. Dreiser G. Herrero-Beaumont A. Kahan G. Kreutz A. Laslop E. M. Lemmel G. Nuki L. Van De Putte L. Vanhaelst J. Y. Reginster. 2004 Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis Osteoarthr. Cartil. 12 263 268
46. P. Richette T. Bardin. 2004 Structure-modifying agents for osteoarthritis: an update Jt. Bone Spine 71 18 23
47. J. DeJongh, D. Eckland, R. J. Heine, and M. Danhof. Pioglitazone efficacy in NIDDM (diabetes type II) therapy: unification of two glycemic control markers by a cascading disease progression model. In M. Danhof, M. Karlsson, and R. J. Powell (eds.), Measurement and Kinetics of in vivo Drug Effects, Leiden/Amsterdam Center for Drug Research, Leiden. Advances in Simultaneous Pharmacokinetic/Pharmacodynamic Modelling, 4th International Symposium, 24-27 April, Noordwijkerhout, 2002.
48. W. DeWinter, T. M. Post, J. DeJongh, R. Urquhart, I. Moules, D. Eckland, and M. Danhof. A mechanistic disease progression model for type 2 diabetes mellitus and pioglitazone treatment effects. 13th Population Approach Group Conference, Uppsala, Sweden, http://www.page-meeting.org, 2004.
49. W. DeWinter, J. DeJongh, B. Ploeger, R. Urquhart, I. Moules, D. Eckland, and M. Danhof. Disease progression modelling; application of population analysis to distinguish between symptomatic and protective treatment effects. 12th Population Approach Group Conference, Verona, Italy, http://www.page-meeting. org, 2003.
50. J. Gabrielsson D. Weiner. 2000 Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications Apothekarsocieteten, Swedish Pharmaceutical Society Stockholm
51. D. E. Mager E. Wyska W. J. Jusko. 2003 Diversity of mechanism-based pharmacodynamic models Drug Metab. Dispos. 31 510 518
52. A. Sharma W. J. Jusko. 1998 Characteristics of indirect pharmacodynamic models and applications to clinical drug responses Br. J. Clin. Pharmacol. 45 229 239